The Manufacturers Life Insurance Company lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 11.2% during the first quarter, HoldingsChannel reports. The institutional investor owned 36,069 shares of the company’s stock after selling 4,560 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Krystal Biotech were worth $9,317,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently added to or reduced their stakes in the company. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech in the fourth quarter valued at approximately $34,000. Sound Income Strategies LLC increased its holdings in shares of Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after acquiring an additional 127 shares during the period. UMB Bank n.a. raised its position in Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the last quarter. Global Retirement Partners LLC boosted its stake in Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after purchasing an additional 142 shares during the period. Finally, Danske Bank A S acquired a new position in Krystal Biotech in the third quarter valued at $35,000. Institutional investors and hedge funds own 86.29% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on the company. Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 1st. Jefferies Financial Group restated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Citigroup increased their price target on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. HC Wainwright lifted their price objective on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research report on Tuesday, June 16th. Finally, TD Cowen boosted their price objective on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $360.67.
Insider Activity at Krystal Biotech
In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,642 shares of company stock valued at $8,243,923 over the last ninety days. 13.10% of the stock is currently owned by company insiders.
Key Headlines Impacting Krystal Biotech
Here are the key news stories impacting Krystal Biotech this week:
- Positive Sentiment: Krystal reported diluted earnings of $1.79 per share, above the $1.73 consensus estimate and up from $1.29 a year earlier. Net income increased to $54.8 million, while VYJUVEK revenue rose 24% year over year to $119.2 million. Krystal Biotech Q2 earnings report
- Positive Sentiment: VYJUVEK demand remained strong, with more than 730 reimbursement approvals and over 640 prescribers. The company expects launches in Spain and Italy before year-end and additional marketing applications in the second half of 2026. Krystal Biotech Announces Second Quarter Results
- Positive Sentiment: The balance sheet remains strong, with $1.1 billion in cash and investments. Investors are also anticipating several pipeline milestones, including KB803 corneal-abrasion data in the fourth quarter and additional updates across respiratory, oncology and dermatology programs.
- Neutral Sentiment: Management projected 2026 non-GAAP research and development plus selling, general and administrative expenses of $175 million to $195 million as VYJUVEK expands internationally. Krystal Biotech operating expense guidance
- Negative Sentiment: Quarterly revenue of $119.2 million was below the approximately $121.8 million analyst forecast. That shortfall appears to have outweighed the EPS beat, particularly given KRYS’s premium valuation.
- Negative Sentiment: SG&A expenses increased to $39.9 million from $35.1 million a year earlier. In addition, pricing and reimbursement negotiations in Germany and France may delay international revenue realization, with discussions extending into late 2026 and 2027. Krystal Biotech shares and revenue miss
Krystal Biotech Trading Down 8.4%
KRYS stock opened at $312.57 on Tuesday. The company’s 50-day moving average price is $339.96 and its 200 day moving average price is $296.59. Krystal Biotech, Inc. has a 52 week low of $130.50 and a 52 week high of $382.54. The company has a market cap of $9.21 billion, a P/E ratio of 41.79 and a beta of 0.53.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, equities research analysts expect that Krystal Biotech, Inc. will post 7.31 earnings per share for the current year.
Krystal Biotech Company Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Articles
- Five stocks we like better than Krystal Biotech
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
